ModeX Therapeutics, a subsidiary of OPKO Health, Launches Clinical Trial for MDX2004 Targeting Advanced Cancers
Clinical Trial Initiation: ModeX Therapeutics has initiated a Phase 1/2a clinical trial for MDX2004, a novel trispecific antibody-fusion protein aimed at treating advanced cancers and immune disorders by enhancing T cell activation.
Mechanism of Action: MDX2004 targets CD3, CD28, and 4-1BB to rejuvenate T cells, potentially improving immune responses in patients with advanced solid tumors and those with immune impairments due to various conditions.
Presentation at SITC: Two abstracts related to MDX2004 will be presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in November 2025, showcasing preclinical and clinical data supporting its development.
About ModeX Therapeutics: ModeX is a biopharmaceutical company focused on developing multispecific biologics for cancer and infectious diseases, leveraging innovative platforms to create effective treatments for complex conditions.
Get Free Real-Time Notifications for Any Stock
Analyst Views on OPK
About OPK
About the author
OPKO Health to Participate in 44th Annual J.P. Morgan Healthcare Conference
- Conference Participation: OPKO Health will participate in the 44th Annual J.P. Morgan Healthcare Conference from January 12-15, 2026, where management will engage in one-on-one meetings with investors, showcasing the company's strategic positioning in the biopharmaceutical and diagnostics sectors.
- Live Webcast: On January 14 at 1:30 p.m. Pacific Time, management will participate in a fireside chat that will be webcast live, allowing investors to gain real-time insights into the company's latest developments and future directions.
- Investor Relations Enhancement: By facilitating direct communication with investors, OPKO Health aims to strengthen its market engagement, enhance its visibility in the biopharmaceutical industry, and further drive its market expansion efforts.
- Industry Positioning: OPKO Health is committed to establishing industry-leading positions in rapidly growing markets by leveraging its expertise in discovery, development, and commercialization, thereby demonstrating its innovative capabilities in the biopharmaceutical and diagnostics fields.
Reasons to Keep OPKO Health Stock in Your Portfolio at This Time
Growth Potential: OPKO Health, Inc. is positioned for growth, particularly due to its leading product RAYALDEE, which has shown solid sales momentum, although the company faces challenges from competition and reliance on this single product.
Financial Performance: The company's shares have declined 10.2% this year, contrasting with industry gains, and it anticipates a 30% growth for fiscal 2026, despite recent earnings misses and a projected revenue decline for Q4 2025.
Strategic Partnerships: OPKO has engaged in several strategic collaborations, including agreements with Regeneron Pharmaceuticals and Entera Bio, aimed at enhancing its product offerings and operational efficiency.
Clinical Trials and Innovations: The company is advancing in clinical trials, including a Phase 1/2a trial for a new oncology treatment and ongoing development of an Epstein-Barr Virus vaccine, indicating a commitment to innovation in its therapeutic pipeline.
